Additionally, one study showed a relationship between RP1L1 mutations and dopamine-agonist resistance in prolactinoma [32], and one meta-analysis identified that PRSS55-RP1L1 was probably associated with the risk of Barrett’s esophagus/esophageal adenocarcinoma in a sex dependent manner [33]. This evidence concerns the gene RP1L1 and esophageal adenocarcinoma.